Primary Cells Market

The global primary cells market is projected to reach USD 2.8 billion by 2028 from USD 1.7 billion in 2023, at a CAGR of 10.5% during the forecast period. The growth of this market can be attributed to factors such as the is the growing advantages of primary human cells over cell lines, growth in pharmaceutical & biotechnology industries, increasing demand for monoclonal antibodies, government investments for cell-based research, and increasing cancer research.

The global primary cells market is competitive, with large, medium-sized, and small market players. The global primary cells market was dominated by Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell Research Laboratories, Inc. (US), ProMab Biotechnologies, Inc. (US), Creative Bioarray (US), BPS Bioscience, Inc. (US), Epithelix (Switzerland), ReachBio LLC (US), AcceGen (US), AMSBIO (UK), and Kosheeka (India).

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific

Thermo Fisher Scientific offers primary cell products through its Biosciences segment. The company has a wide customer base, including pharmaceutical and biotechnology companies, hospitals and clinical laboratories, universities, research institutions, government agencies, and environmental and process control industries. It has a strong geographic footprint and operates across North America, Europe, Latin America, and Asia. From 2020 to 2022, Thermo Fisher Scientific has engaged in strategic developments such as geographic expansions. The organization is expected to witness significant growth in the global primary cells market with its strong product portfolio, continuous research & development activities, and broad geographic reach.

Merck

Merck was one of the leading players in the primary cells market in 2022. Merck has expanded its position as the most profitable supplier in the primary cells industry by offering leading-edge products for biotechnology & pharmaceutical companies and for the advancement of cell and gene therapy. With a strong geographic presence, a broad portfolio of primary cell products, and continuous expansions in developed as well as developing regions, the company is expected to grow at a high rate in the primary cells market during the forecast period. The company also focuses on enhancing its presence in the high-growth Asian region to increase its market share and revenue. In the last three years, the company has opened life science centers in China, India, South Korea, and Singapore.

Related Reports:

Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region- Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]